2. A. Blood Test
Sample Collection
Venipuncture
Capillary Blood by Skin Puncture
Done when venipuncture cannot be performed or when reducing frequency of needle sticks
is desired and less painful
3. A.1 FASTING BLOOD GLUCOSE TEST
Person to be tested should be on normal diet for at least 3 days prior to testing
Fasting for 8 – 12 hours
Plasma or serum is used instead of whole blood
More readily measured on automated equipment
Glucose concentration is 10 – 15% higher than in whole blood
5. A.2.a ORAL GLUCOSE TOLERANCE TEST
Fasting for 8 – 12 hours
Patients requested to drink anhydrous glucose dissolved in 250 – 300mL water
Adults: 75g anhydrous glucose
Children: 1.75g/kg of body weight anhydrous glucose
Blood tested regularly in 30 minutes interval
In conditions of insulin defiency, blood glucose levels got elevated due to impaired
utilization of glucose
Required for confirmation
Glucose Tolerance Curve is then plotted
9. A.2.b Intravenous Glucose Tolerance Test
Undertaken for patients with malabsorption
Patient is given 25g of glucose dissolved in 100mL distilled water as intravenous
injection within 5 minutes
Blood samples drawn at 10 minutes interval for the next 2 hours
Interpretation:
Normal individuals, blood glucose level returns to normal within 60 minutes
Diabetes mellitus – decline is slow
11. A.2.c Mini or Modern GTT
Two samples are collected
Fasting (zero hour)
2 Hour Post Glucose Load
Zero Hour After 2 Hours
Normal Person < 110 mg/dL < 140 mg/dL
Diabetic Person > 126 mg/dL > 200 mg/dL
Increase Glucose Tolerance 110 – 126 mg/dL 140 – 199 mg/dL
12. A.3 Post Prandial Blood Sugar
Patient advised to have normal meal
Blood collected 2 hours after meal
Glucose Level
Normal < 140 mg/dL
Pre-diabetic 140 – 200 mg/dL
Diabetic > 200 mg/dL
13. A.4 Random Blood Glucose
Only required during emergency
Diabetis Mellitus: > 200 mg/dL
14. A.5 HbA1c
Test that measures amount of glycated haemoglobin in your blood
Glycated haemoglobin is a substance in red blood cell that is formed when blood
sugar attaches to haemoglobin
Generally reflect the state of glycemia over the preceding 8 – 12 weeks thereby
providing an improved method of assessing diabetic control
17. Self monitoring blood glucose (SMBG)
People who take insulin should regularly self monitor
blood glucose.
For people with non-insulin treated type 2 diabetes
testing is most useful if patients use the results to learn
and alter behaviour, or medication.
“...SMBG is most useful if patients use
the results to learn, as part of an overall
diabetes education package….”
18. Laboratory tests to prevent and delay
complications of diabetes
People with diabetes usually die from
macrovascular complications of their
diabetes; namely cardiovascular disease.
This is influenced by all of the commonly
recognised risk factors for cardiovascular
disease as well as glycaemic control.
Fasting lipid levels are measured three
monthly until stable and then 6 - 12
monthly thereafter.
It is important that management should be
individualised
Parameter Optimal value
Total
cholesterol
< 4 mmol/L
LDL cholesterol < 2.5 mmol/L
HDL cholesterol > 1 mmol/L
TC:HDL ratio < 4.5
Triglycerides < 1.7 mmol/L
HbA1C < 7 mmol/L
19. Diabetic renal disease
The best way of testing for diabetic renal disease is by urinary albumin:creatinine ratio
(ACR) and serum creatinine with estimated glomerular filtration rate (eGFR). These tests
are performed on everyone with diabetes at diagnosis and repeated at least annually –
more frequently if there is proteinuria, microalbuminuria or reduced eGFR.
Albumin:creatinine ratio
ACR provides an estimate of daily urinary albumin excretion.
Microalbuminuria cannot be detected on a conventional urinary protein dip stick.
Microalbuminuria is urinary albumin excretion between 30 and 300 mg/day; above
300mg/day represents proteinuria.
ACR is best measured in the laboratory using a first morning urine sample where
possible when the patient is well.
An abnormal initial test requires confirmation by testing on two further occasions. If
at least one of these tests is positive microalbuminuria has been confirmed.
20. Renal testing in diabetes
*Non-diabetic renal disease is suspected when there is absence of diabetic retinopathy in a person
with renal disease, there are urinary abnormalities such as haematuria or casts, or when there is
renal disease without microalbuminuria or proteinuria.
ACR
mg/mmol
(confirmed)
eGFR
mL/min/1.
732
Risk Management
men < 2.5
women < 3.5
and > 60
2 - 4% per year
progress to
microalbuminuria.
Annual ACR and eGFR. Good diabetes &
BP management.
men ≥ 2.5
women ≥ 3.5
or < 60
One third progress to
overt nephropathy.
CVD risk doubled.
Review ACR and eGFR at each visit.
Intensive management of glycaemia
and CVD risk factors.
Use ACE inhibitor and low-dose aspirin.
Avoid nephrotoxic drugs.
Investigate if suspicious of causes other
than diabetes*
> 30 or < 30
Almost all proceed to
end stage renal
disease or die
prematurely of CVD.
Overt nephropathy
Refer specialist
21. Other tests
Testing of LFTs is recommended for people with diabetes:
at diagnosis,
at the start of antidiabetic drug therapy, and
at any other time indicated by clinical judgement
Other laboratory tests
In patients with type 1 diabetes, intermittent checks for
other autoimmune conditions may be useful. This could
include testing for thyroid dysfunction or coeliac disease.
22. 22Urinary Glucose
-Glucose can be detected in urine using the specific test strips that contain
glucose
oxidase, peroxidase, and a chromagen.
-Other carbohydrates using Benedict's and Febling's reagents.
23. 23Urinary Ketones
-Acetone and acetoacetic acid can be detected in urine using the AcetesTM or
KetostixTM systems.
-These tablets or strips use nitroprusside (sodium nitroferricyanide) to detect
ketones.
24. 24Urinary Ketones
-Because beta-hydroxybutyric acid lacks a ketone group is not detected by
this assay.
-Quantitative assays for acetoacetate and beta-hydroxybutyric acid are
available using beta-hydroxybutyrate dehydrogenase and either NADH or
NAD.
25. 25Urinary Ketones
-If NAD is used as the cofactor and the reaction is buffered at around pH
9.0, beta-hydroxyburyric acid is measured.
-On the other hand, a separate reaction using NADH and buffered around
pH 7.0 would measure acetoacetic acid.
26. 26Microalbuminuria
-Diabetes mellitus causes progressive changes to the kidneys and ultimately
results in diabetic renal nephropathy.
-This complication progresses over a period of years and may be delayed by
aggressive glycaemic control.
-An early sign that nephropathy is occurring is an increase in urinary albumin.
27. 27Microalbuminuria
-Microalbumin measurements are useful to assist in diagnosis at an early
stage and
prior to the development of proteinuria.
-Microalbumin concentrations are between 20 to 300 mg/d.
-Proteinuria is typically greater than 0.5 g/d.
28. 28Proteinuria in Diabetes
- Many people excrete small quantities of protein in urine, typically around 10
mg/day of mainly low molecular weight proteins such as albumin.
-Some diabetic patients develop albumin excretion rates 30 µg/min this range
classed as microalbuminuria.
29. 29
METHODS FOR THE DETERMINATION OF GLUCOSE
The most used
methods of
glucose analysis
employ the enzymes
glucose oxidase or
hexokinas.
A) Glucose
Oxidase
B) Hexokinase
30. 30
SELECTED METHODS FOR THE MEASUREMENTS OF GLYCATED HAEMOGLOBINS
InterferenceMeasurementMethod
Carbamyl Hb
HbF
Temperature-
sensitive
HbA1cCation exchange
HbA1cMonoclonal antibody
Glycated HbAffinity chromatography
Phenyl boronate matrix
Latex agglutination
Fluorescence quenching
31. ReferencesColagiuri, S., et al. (2003). Comparability of venous and capillary glucose measurements in blood.
Diabetic Medicine, 20,953-956.
Franciosi, M., et al. (2001) The impact of blood glucose self-monitoring on metabolic control and
quality of life in type 2 diabetic patients. Diabetic Care, 24,1870-77.
Harris, H. (2005). Elevated liver function tests in type 2 diabetes. Clinical Diabetes, 23, 115-119.
Kenealy, T et al. (2004). Diabetic care by general practitioners in South Auckland: changes from
1990 to 1999. The New Zealand Medical Journal,115,219.
Kjos, S., Buchanan, T. (1999). Gestational Diabetes Mellitus. New England Journal of Medicine,
341, 1749-1756.
NZGG: New Zealand Guidelines Group. (2003). Management of Type 2 Diabetes. Available at:
http://www.nzgg.org.nz/guidelines/0036/Diabetes_full_text.pdf (accessed March 2006)
NZGG: New Zealand Guidelines Group. (2003). Assessment and Management of Cardiovascular
Risk. December 2003. Available at: http://www.nzgg.org.nz/guidelines/0035/CVD_Risk_Full.pdf
(accessed March 2006).
Schwedes, U., Siebolds, M., and Mertes, G. (2002). Meal-related structured self-monitoring of
blood glucose. Diabetes Care, 25,1928-32.